«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2014年第2期

页码:

207-209

栏目:

临床研究

出版日期:

2014-01-20

文章信息/Info

Title:

Clinical study of therapeutic effects and safety of erythropoietin treatment for elderly patients with chronic heart failure

作者:

陈振云¹; 陈 侃²; 熊海刚¹; 刘祖秋¹; 俞飞虎¹; 晏 彪¹

(1.解放军第113医院心内科，浙江 宁波 315040；2.第二军医大学附属长征医院心内科，上海 210003)

Author(s):

CHEN Zhen-yun¹;  CHEN Kan²;  XIONG Hai-gang¹;  LIU Zu-qiu1;  YU Fei-hu¹;  YAN Biao¹

(1.Department of Cardiology, PLA 113th Hospital, Ningbo 315040, Zhejiang, China; 2.Department of Cardiovasology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China)

关键词:

促红细胞生成素; 心力衰竭; 慢性; 心功能分级

Keywords:

erythropoietin;  chronic heart failure;  heart function classification

分类号:

R542.2

DOI:

-

文献标识码:

A

摘要:

目的:探讨促红细胞生成素（EPO）对老年慢性心力衰竭（CHF）患者的临床疗效、心功能分级、运动耐量影响及毒副作用。方法： 将80例CHF患者随机分成试药组（n=40）和对照组（n=40）。采用常规口服稳定剂量的利尿剂、地高辛、血管紧张素转换酶抑制剂（ACEI）或血管紧张素Ⅱ受体拮抗剂（ARB）、β受体阻滞剂等药物。试药组在对照组基础上皮下注射EPO 100 U/kg，每周1次，治疗6个月。结果： 试药组EPO治疗前后相比心功能测定LVEF、6分钟步行距离、心肌耗氧量峰值、血红蛋白均有显著改善（P<0.05），组间比较贫血组较非贫血组显著改善（P<0.05）。结论： EPO能改善CHF患者的心功能状态和临床症状，并提高运动耐量，且与贫血状态改善有关。

Abstract:

AIM:To study the effect and safety of erythropoietin (EPO) in the treatment of chronic heart failure (CHF) in elderly patients. METHODS: Eighty patients with CHF were randomly divided into two groups. Patients in the control group (n=40) were administered the routine treatment of CHF (diuretics, digoxin and ACEI), whereas in addition to the routine treatment, patients in the study group (n=40) were given a dose of EPO, 100 U/kg IH, once a week for 6 mouths. Left ventricular ejection fraction (LVEF) and hemoglobin (Hb) were measured, respectively, by echocardiography and laboratory examination. Heart function was examined by 6-min walking distance and NYHA heart function classification. RESULTS: Obvious improvements in LVEF, Hb, 6-min walking distance and NYHA heart function classification were observed in the study group after 6 months administration of EPO. The therapeutic effect was significantly different between groups (P<0.05). CONCLUSION: EPO treatment is safe and effective for improving heart function and enhances exercise tolerance in CHF patients.

参考文献/References

[1]张树风,戴启明.促红细胞生成素在心血管疾病中的作用研究进展[J].心血管病血进展,2012,3(33):407-410.
[2]庞 英,马建群.促红细胞生成素的心血管作用[J].心血管病血进展,2008,29(1):139-141.
[3]Mancini DM,Katzs D,Lang CC,et al.Effect of erythropoietin on exercise capaxity in patient with moderate to severe chronic heart failure[J].Circulation,2003,107(1):294-299.
[4]Ezekowitz JA McalisterFA,Amstrong PW.Anemia is Cocumon in heart failure and is associated with poor outcomes:insights from a cohort of 12 065 patients with new-onset heart failure[J]. Circulation,2003,107(2):223-225.
[5]van der Meer P,Voors AA,Lipsic E,et al.Erythropoietin in cardiovascular disease[J].Eur Heart J,2004,25(4):285-291.
[6]van der Meer P,Voors AA,Lipsic E,et al.Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure[J].J Am Coll Cardiol,2004,44(1):63-67.

备注/Memo

备注/Memo:

收稿日期：2013-06-27.
作者简介：陈振云，主任医师，硕士Email：CZY8lnk@163.com

常用功能

更新日期/Last Update: 2014-01-16